Michael Rotkowitz, MD

Michael Rotkowitz, MD, says that one of the main challenges and a leading goal of immunotherapy research is measuring response to justify the administration.

Michael Rotkowitz, MD, from Cancer Treatment Centers of America, discusses a phase III trial that examined ipilimumab plus dacarbazine for patients with metastatic melanoma.

Dr. Michael Rotkowitz, from Cancer Treatment Centers of America, Defines Personalized Medicine

Dr. Michael Rotkowitz, from Cancer Treatment Centers of America, on Dabrafenib and Trametinib Combination Side Effects

Dr. Michael Rotkowitz, from Cancer Treatment Centers of America, on the Dabrafenib Plus Trametinib Combination for Melanoma